Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Pei Li Teh
  • September 22, 2020
  • Articles

Developing Biosimilars in Asia

Developing Biosimilars in Asia

Biologics currently make up half of the pharmacological market for oncology, but the steep cost of these drugs is a barrier to access globally.

In 3 years’ time, patents on nearly 20 oncology biologics will expire, which is likely to result in the launch of biosimilars offering reduced prices. In the past, the biosimilars market was focused in Europe and the US. However, biosimilars have recently begun to emerge in countries with existing biopharmaceutical infrastructure and companies.

read more »

How we helped our client to evaluate early biosimilar user experience

How we helped our client to evaluate early biosimilar user experience

Our client wanted to evaluate early user experience for physicians and patients across Europe of a newly launched biosimilar in an autoimmune disease. The results were needed to better understand drivers and barriers of prescribing/using biosimilars (vs. biologics) and suitable patient types to develop more targeted communication material.

read more »

  • Posted by Rachel Howard, Brett Gardiner & Richa Munjal
  • June 8, 2020
  • Articles

Breaking policy and perceptual barriers: Biosimilars

Breaking policy and perceptual barriers: Biosimilars

Our specialist market access and Therapy Watch teams analyse RA prescribing data to identify how market access policies across Europe may have impacted the adoption of biosimilars. Read our latest article for pharmaphorum's Deep Dive.

Biologics are big business in Rheumatoid Arthritis (RA), with the first wave of TNF inhibitors Remicade (infliximab), Enbrel (etanercept) and Humira (adalimumab) all having achieved blockbuster sales since their launches in the early 2000s. In recent years, as patents started to expire, an increasing number of branded and generic pharmaceutical companies have launched biosimilars, offering meaningful discounts relative to the originators – an appealing proposition for strained healthcare systems under pressure to contain costs. Leveraging over two years of syndicated RA Therapy Watch data* from September 2017-December 2019 in France, Germany, UK, Italy, and Spain, we looked into what parallels could be drawn between country trends in biosimilar prescribing and individual market policies designed to promote their use.

read more »

  • Posted by Laurent Chanroux
  • March 30, 2017
  • Articles

What next for the treatment of Psoriasis in Europe?

What next for the treatment of Psoriasis in Europe?

Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.

Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease.

read more »

  • Posted by Mariel Metcalfe
  • January 23, 2017
  • Articles

Biosimilars: Bringing patients into the conversation

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe

In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA treatment. We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance.  

read more »